anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a nanoparticle, in an aqueous solution, of a concentration similar to concentration of the nanoparticle in the synthesis in an organic solution, without no restrictions from a viewpoint of the use of the nanoparticle in future.  &lt;P&gt;SOLUTION: This nanoparticle contains a hydrophobic component Y(12), a hydrophilic component X(16) and an organic molecular component Z(14). The phase transfer method is to transfer an inorganic colloidal particle from an organic phase to a water phase or an alcohol phase which is immissible with the organic phase, using a phase transfer catalyst bonding the component X and the component Y together. The hydrophobic component Y(12) contains a thiol group and the hydrophilic component X(16) contains a carboxyl group. After completing the phase transfer, the water phase or the alcohol phase is separated from the organic phase.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
The invention discloses a core/shell-type multifunctional nano material and a preparation method thereof. The core of the multifunctional nano material is an up-conversion nano luminescent material and the shell is an alkaline manganese compound, nano golden particles deposited between the core and the shell. The core/shell-type multifunctional nano material achieves fluorescence detection and magnetic resonance imaging analysis at the same time, wherein the core material is a rare earth up-conversion nano luminescent material, so that a fluorescent marking/imaging function can be achieved. The shell material is the alkaline manganese compound, which is decomposed into an MRI contrast agent Mn&lt;2+&gt; when the material enters a tumor cell, so that MRI imaging of the tumor cell can be achieved accurately. Meanwhile, the material releases the fluorescence up-conversion core material to achieve up-conversion fluorescence imaging. The nano golden has the photo-thermal effect and CT imaging function, so that when the material enters the tumor cell, the material not only achieves fluorescence/MRI double-function imaging but also achieves CT imaging and photo-thermal therapy.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a membrane having bioabsorbability and satisfactorily high mechanical strength, quickly and efficiently inducing osteoanagenesis and tissue anagenesis and enabling the treatment of bone regeneration and tissue regeneration by a single operative treatment.  &lt;P&gt;SOLUTION: The gelatin hydrogel membrane of the invention for the periodontal surgical treatment has a double-layer structure having shielding function and sustained drug release function. The GTR (guided tissue regeneration) membrane and the GBR (guided bone regeneration) membrane used in the periodontal surgical treatment have two characteristics. One is the compatibility of the decomposition life of about 3 months and the strength to endure the breakage of the yarn, and the other is the sustained release of the drug over about 2 weeks. Accordingly, the invention uses a gelatin hydrogel mechanically reinforced with a bioabsorbable material for ensuring the bone regeneration space for a long time. Further, the use of a gelatin hydrogel having a sustained drug releasing function at the inner side (the space-side of bone regeneration) as a double-layer structure promotes the supply of oxygen and nutrients by angiogenesis, causes the induction of the regeneration of the bone tissue and the peripheral tissue and enables the quick and efficient treatment.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a process for producing a solid powder cosmetic which can easily yield a solid powder cosmetic showing an excellent impact resistance and sensory evaluation.  &lt;P&gt;SOLUTION: In the process for producing the solid powder cosmetic, a granulated substance made from a mixture containing a powder and an oil is pressure molded to obtain the solid powdery cosmetic. Upon pressure molding, the granulated substance has a particle size distribution wherein a particle size D50 corresponding to a cumulative frequency in the particle size distribution of 50% is 5-30 μm and a value (D90-D10)/D50 is ≤3. The mixture further contains a polymer dispersion. The powder is preferably hydrophobic or hydrophobed, and a polymer composing the polymer dispersion is preferably a coating film- forming polymer having an elastic modulus of 0.3-200 kg/cm&lt;SP&gt;2&lt;/SP&gt;.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to new emulsions of type &#34;oil-in-water&#34; that can be used for parenteral administration into the body biologically active steroids exhibiting the limited solubility in usual solvents. Lipid phase of an emulsion has castor oil and phospholipid emulsifier made of an egg yolk. The content of components per 1 ml of an emulsion is the following: steroid from 0.1 to 15 mg, castor oil from 50 to 200 mg and an emulsifier - an egg yolk phospholipids from 5 to 50 mg. For emulsion preparing steroids are dissolved in lipid phase and the formed steroid-lipid phase is emulsified in an aqueous phase containing water and an egg yolk phospholipids. The novel emulsion has significant amounts of steroids dissolved in lipid phase in combination with increased physical and chemical stability that results to decrease of the total lipid loading and amounts of solubilizing and stabilizing agents administrated in the patient organism. EFFECT: improved quality and properties of an emulsion. 8 cl, 5 ex
A culture method for determining the effect of a biological agent on multipotent neural stem cell progeny is provided. In the presence of growth factors, multipotent neural stem cells are induced to proliferate in culture. The multipotent neural stem cells may be obtained from normal neural tissue or from a donor afflicted with a disease such as Alzheimer&#39;s Disease, Parkinson&#39;s Disease or Down&#39;s Syndrome. At various stages in the differentiation process of the multipotent neural stem cell progeny, the effects of a biological agent, such as a virus, protein, peptide, amino acid, lipid, carbohydrate, nucleic acid or a drug or pro-drug on cell activity are determined. Additionally, a method of screening the effects of biological agents on a clonal population of neural cells is provided. The technology provides an efficient method for the generation of large numbers of pre- and post-natal neural cells under controlled, defined conditions. The disclosed cultures provide an optimal source of normal and diseased neural cells at various developmental stages, which can be screened for potential side effects in addition to testing the action and efficacy of different biological agents.
Systems and methods are provided for setting up and sending healthcare alerts (e.g. immunization reminders) to patients/caregivers through the use of communications devices. In an embodiment, information about a patient&#39;s/caregiver&#39;s wireless device (e.g. cell phones) is collected and reported to an immunization registry. The registry is linked to a system that uses the wireless device information to generate automatic wireless immunization reminders, recalls and educational messages that are sent to the patient/caregiver. In a preferred embodiment, opt-in information is reported to the system to ensure that the patient/caregiver has consented to the automatic wireless immunization reminders. The system may also check the eligibility of patients to receive reminders, provide incentives for patients to receive reminders, provide follow up information (e.g. performed, not performed, responses to message/s) to a healthcare provide for a particular patient or a group of patients, and/or provide billing services for payment of the reminders.
To provide neural stem cell compositions and methods for treating neurodegenerative disorders.SOLUTION: The disclosure provides a stem cell-based therapy for treating a neurodegenerative disease and CNS disorder such as Huntington&#39;s disease. The therapy has improved motor deficits and rescued synaptic alterations. The cells were shown to be electrophysiologically active and to improve motor impairment and later-stage cognitive impairment. In some embodiments, the method further comprises genetically modifying the cell. In some embodiments, the cell is genetically modified by insertion of a transgene, or by modification by CRISPR. In some embodiments, the transgene is ApiCCT1, a fragment thereof, or an equivalent of each thereof, and optionally the transgene is overexpressed in the cell.SELECTED DRAWING: None
NEW MATERIAL:The compound of formula I {a is 0-2; b is 0-4; R&lt;1&gt; is 1-4C monohydroxyalkyl, dihydroxyalkyl, group of formula II (R&lt;2&gt; and R&lt;3&gt; are 1-4C alkyl) or formula III [c and d are 1-4; X is O or N-R&lt;4&gt; (R&lt;4&gt; is H or 1-3C alkyl)]}. USE:A medicine. An antibacterial agent. It is soluble in a number of solvents, exhibits strong antibacterial activity against Gram-positive bacteria and acid-fast bacteria and has low toxicity. It can be used as a production raw material for a novel rifamycin derivative of formula IV having strong antibacterial activity. It is administered daily for adults at a rate of 10mg-10g of the active component. PREPARATION:The compound of formula I can be produced by reacting rifamycin O or S with an o-aminophenol compound of formula V in an organic solvent such as benzene to obtain an intermediate, substituting the solvent with another organic solvent such as methanol and reacting the intermediate in the presence of an oxidizing agent such as MnO2.
A dietary mixture substantially free from phenylalanine, and from aspartic and glutamic acids, is prepared by treating a protein acid hydrolysate with an anion-exchange resin on the hydroxide cycle simultaneously to neutralize the hydrolysate and adsorb the aspartic and glutamic acids, contacting the neutralized hydrolysate with charcoal to adsorb phenylalanine, isolating the resulting protein hydrolysate and converting the residual glutamic acid therein to pyrrolidone dicarboxylic acid e.g. by autoclaving.  A solution of the essential amino acids leucine, isoleucine, valine, methionine, treohnine, arginine, histidine and lysine may be so obtained, and the natural essential amino acid tyrosine, racemic essential amino acids comprising tryptophane and methionine, and the non-essential amino acid glycine, may be added thereto to prepare an orally administrable dietary mixture containing not more than 1% phenylalanine, not more than 5% aspartic and glutamic acids and not more than 3% racemic essential amino acids comprising tryptophane and methionine.  The hydrolysate may be derived from casein, lactalbumin, egg albumin, fibrin, blood serum albumin, and serum globulin, and mixtures thereof, and the anion exchange resin may be a polyamine resin.ALSO:A dietary mixture substantially free from phenylalamine, and from aspartic and glutamic acids, is prepared by treating a protein acid hydrolysate with an anion exchange resin on the hydroxide cycle simultaneously to neutralize the hydrolysate and adsorb the aspartic and glutamic acids, contacting the neutralized hydrolysate with charcoal to adsorb phenylalamine, isolating the resulting protein hydrolysate and converting the residual glutamic acid therein to pyrrolidone dicarboxylic acid, e.g. by autoclaving.  A solution of the essential amino acids leucine, isoleucine, valine, methionine, threonine, arguinine, bistidine, and lysine, may be so obtained, and the natural essential amino acid tyrosine, racemic essential amino acids comprising tryptophane and methionine, and the new-essential amino acid glycine, may be added thereto to prepare an orally administrable dietary mixture containing not more than 1% phenylalanine, not more than 5% aspartic and glutamic acids and not more than 3% racemic essential amino acids comprising tryptophane and methianine.  The hydrolysate may be derived from casein, lactalbumin, egg albumin, fibrin, blood serum albumin, and serum globulin, and mixtures thereof, and the anion exchange resin may be a polyamine resin.  A crystalline mixture of &#34;fortifying&#34; ingredients may be included in dietary preparations containing the protein hydrolysate.
The present invention provides compositions and methods for transplanting cells into a solid organ by an implantation strategy. These methods and compositions are useful for repairing diseased organs or for modeling disease states in experimental hosts. The method involves attaching a patch implant, a &#34;bandage-like&#34; covering, to the surface of a tissue or organ, the &#34;bandage-like&#34; covering containing epithelial cells as well as mesenchymal cells during supportive early lineage. The cells are incorporated into a gel-forming biomaterial that is prepared under serum-free, defined conditions that collectively support the sternness of the donor cells. The implant is covered with a biodegradable, biocompatible, bioresorbable substrate for immobilizing the implant at a target site. The cells in the implant migrate to and throughout the tissue such that they are evenly dispersed within the recipient (host) tissue within two weeks. The mechanism of donor cell implantation and integration into the organ or tissue involves multiple membrane-associated and secreted forms of MMPs.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a combination drug in which interferon and various kinds of cytokines are produced in the human body, their proliferations and antagonisms are solved by dependence on orders in vivo and essential immune strength of a user is exhibited to maximum to bring about great effect mainly on treatment of cancers.  &lt;P&gt;SOLUTION: The combination drug is obtained by blending an organic mineral component with a polysaccharide and gluconsamine. The organic mineral component is extracted from ocean planktons and lactic acid bacteria. The organic mineral component is organic ionized calcium. The polysaccharide is an oligosaccharide. The oligosaccharide is an oligosaccharide having ≤1,000 molecular weight of the center of the hexamer. The organic mineral component and the polysaccharide are both processed into a powdery state, mixed, capsulated, tableted or made into syrup.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
PURPOSE:A melanin inhibitor, containing a specific cinnamic acid derivative as an active constituent, and having a high safety without unrecognized development of irritancy nor allergy to the skin, etc. CONSTITUTION:A melanin inhibitor containing a compound of the formula (R&#39; is 2-8C acyl; R is H, 1-6C alkyl, cycloalkyl or alkenyl), e.g. methyl p-acetyloxycinnamate, as an active constituent. Preferably, the compound of the formula is incorporated in the inhibitor in an amount of 0.01-50wt%, particularly 1- 20wt% based on nonvolatile components in the inhibitor. Furthermore, the addition of allantoin, glycyrrhizin, coix seed or extracts of various plants, etc. improves the inhibitory effect on melanin, and the addition of an ultraviolet light absorbing substance provides a melanin inhibitor having both the preventing and remedial effects on sunburn. The inhibitor is applied locally to a liver spot, ephelis and pigmented site after sunburn of the skin to treat and improve the site and return the site to the normal color of the skin.
PURPOSE:To provide the titled agent containing dihydrochikusetsu-saponin III as a main component, and having blood activation effect. CONSTITUTION:A respiratory complement having blood activation effect is prepared by using dihydrochikusetsu-saponin III of formula as a main component. Preferably dose in an urgent blood activation in flooding is 15-25mg/dose for intravenous injection and 50-100mg/dose for oral administration, and &lt;=3 doses a day. The agent is effective to improve the function of blood in the case of flooding in major operation, etc., and to recover the fatigue quickly. It is also useful for the improvement of intractable diseases such as rheumatism, neutralgia, etc. by continuous use for a long period, and for the maintenance of health. The main component can be prepared by crushing the rhizome of Panax japonicus, extracting with hot water containing 50% of methanol, concentrating the extract liquid, extracting the concentrated aqueous solution of the extract with n-butanol, and subjecting the resultant extract e.g. to counter-current partition, etc.
NEW MATERIAL:A compound shown by the formula I (X is halogen; R1 is H, CH3, or C2H5; R2 is 1-4C alkoxy) and its acid addition salt. EXAMPLE:5&#39;-Chloro-2&#39;-methoxy-3-piperidinopropiophenone hydrochloride. USE:A remedy for spastic obdormition. PROCESS:A compound shown by the formula II is reacted with a formaldehyde and piperidine shown by the formula III or its salt preferably in a solvent such as ethyl acetate, etc. preferably at the reflux temperature of the solvent to give a compound shown by the formula I . Piperidine is usually used as a salt of mineral acid such as hydrochloric acid, hydrobromic acid, etc., but free piperidine can be used if the mineral acid is added to a reaction system to acidify it sufficiently.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a brain function promoting agent having excellent promoting effect on the release of a neurotransmitter.  &lt;P&gt;SOLUTION: This brain function promoting agent contains an active component composed of limonene or its metabolic products expressed by the formula, preferably a metabolic product of limonene. The metabolic product of limonene is e.g. perillic acid or perillyl alcohol. The limonene and its metabolic products are preferably S-form rather than R-form. The neurotransmitter is one or more substances selected from norepinephrine, epinephrine, dopamine and serotonin.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
In some embodiments, a method may include treating brain cancer sensitive to cytotoxic effect. The method may include intraventricularly administering to a subject via a subject&#39;s cerebrospinal fluid an effective amount of a pharmaceutical formulation. The pharmaceutical formulation may include at least one chemical compound. In some embodiments, the pharmaceutical formulation may include at least one aqueous diluent. The at least one chemical compound may include a molecular weight of between about 400 MW and about 10,0000 MW. The at least one chemical compound may include protein binding of greater than 30% and greater than 70 Angstroms in cross sectional area. In some embodiments, the at least one chemical compound includes Irinotecan, SN-38, and/or a related derivative thereof. In some embodiments, the method may include ameliorating and/or inhibiting brain cancer in the subject using the pharmaceutical formulation.
A method and system of selling healthcare services to a patient. A number of healthcare service providers are contracted and registered with a healthcare marketplace operator (32). Information regarding the healthcare providers is stored in a database (48). A prospective patient is provided with a case statement template having one or more areas to specify clinical and non-clinical requirements of the patient. The patient uses the template to provide case statement information to the marketplace operator. In many instances, the case statement template is completed with the assistance of the patient&#39;s primary physician. The case statement information is received and processed by the marketplace operator. The marketplace operator generates a case statement from the case statement information and the case statement is made available or distributed to contracting healthcare providers.
PURPOSE: A composition using aloin, aloesin, or aloe gel is provided to prevent deletion of colon mucosa and to lower leukotriene B4, TNF-alpha and PGE2 plasma concentration. CONSTITUTION: A composition for treating inflammatory bowel diseases contains aloesin as an active ingredient. The inflammatory bowel diseases are ulcerative colitis, crohn&#39;s disease, celiac disease, intestinal Behcet disease, celiac disease, or ischemic enteritis. The composition is a pharmaceutical composition or food composition. The pharmaceutical composition contains pharmaceutically acceptable carrier and excipient. The pharmaceutical composition is manufactured in the form of an oral formulation(tablet, suspension, granule, emulsion, capsule, syrup), parenteral formulaion(aqueous or oil suspension for sterilization infection), and topical formulation(solution, cream, ointment, gel, lotion, patch).
The present invention provides a system for treating heart disease as a &#39;bridge to recovery&#39; using cellular cardiomyoplasty. The system is particularly useful in selecting and treating patients with damaged myocardium due coronary artery disease, myocardial infarction, congestive heart failure, and ischemia. Based on various clinical criteria, a patient is selected and optionally treated using cellular cardiomyoplasty to improve the patient&#39;s cardiac function. The cardiomyoplasty may be combined with other treatments such as medications or left ventricular assist devices. Preferably, the cellular cardiomyoplasty eliminates the need for invasive surgery such as by-pass grafting or cardiac transplantation. The invention also provides kits for use in selecting and treating patients using the inventive method.
Two very important factors in human life—which play vital roles in promoting well being—includes returning the body to homeostasis and giving boost to body called lifeforce to get overall health free from diseases, i.e., its optimal balanced functioning ability. When the body is at homeostasis, there is no place for disease. It is only when the body is out of balance (something is deficient, in excess or stagnating) that pain, illness or disease can occur. The application described is based on returning the body to homeostasis (removing the problem and balancing the body) by providing lifeforce and not on dealing with the symptom (e.g., pain, vitamin deficiency). Imbalance results in various diseases and adverse health conditions (starting from aging to diabetes and cancers). This wonderful composition will interact with the body in a way that allows it to boost lifeforce and reach homeostasis no matter which direction it was. In this combination, in the form of liquid, all the 14 ingredients ( Lepidium meyenii  (Maca),  Croton planstigma  (Dragon&#39;s blood) tree sap,  Uncaria tomentosa  (Cat&#39;s Claw),  Morinda citrifolia  (Noni fruit) 4:1 PE, Lutein, Lycopene 5%, Flaxseed Oil (Omega-3-Fatty Acids), Vinpocetine, Phosphatidyl Serine 50%, Korean Ginseng 80%,  Bacopa monnieri  (Bacopin), CDP Choline (Cognizing), Guaranine (Guarana Seed PE 12%), Yerba Mate Ext. 8%) work as mixture for returning the body to homeostasis and give it lifeforce.
PURPOSE:To adsorb and remove malodorous components while well maintaining a hygienic state by depositing deodorant particles. on an org. high-polymer material matrix. CONSTITUTION:The calcium phosphate compd. to be used as a deodorant is made into the particles which have 1.0 to 2.0Ca/P ratio, are in the form of granules or porous granules and have 0.1 to 2000mum grain size and 0.1 to 100m&lt;2&gt;/g specific surface area. Such deodorant is deposited on paper, gauze, nonwoven fabric or plastic foam as the org. high-polymer material matrix.